Because the resistance to DDP treatment is a major clinical issue in ovarian cancer, we wondered that CYLD expression could be linked to cisplatin resistance, and found the expression levels of CYLD were much lower in cancer tissues of the cisplatin resistant group than in the sensitive group (Fig. 2A). The gene discussed is CYLD; the disease is ovarian cancer.